MorningstarNovo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market OverenthusiasmMay 2Karen AndersenBy Karen Andersenmore_vert
Sky NewsIan King Business Podcast: Goldman Sachs removes bonus cap, demand for gold and Novo Nordisk forecastsMay 2more_vert
매일경제Model and entrepreneur Kim Kardashian and Tesla CEO Elon Musk are known to have been effective, so t.. - MKMay 3more_vert
geneonlineNovo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 BillionMay 3more_vert
MM+M OnlineBig Pharma Q1 earnings roundup: Novo, Moderna and Regeneron reportMay 2Jack O'BrienBy Jack O'Brienmore_vert
BloombergSticking to Bolt-on M&A Strategy: Novo Nordisk CFO | The Pulse with Francine Lacqua 05/02/24May 2more_vert
Yahoo FinanceNovo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call TranscriptMay 3Insider MonkeyBy Insider Monkeymore_vert
BioSpaceNovo’s Q1 Revenue Grows 24%, Raises Guidance as Wegovy Sales SurgeMay 2Tristan ManalacBy Tristan Manalacmore_vert
CNBCNovo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the companyMay 2more_vert
Pharmaceutical TechnologyNovo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1May 2Phalguni DeswalBy Phalguni Deswalmore_vert
QuartzWeight loss drug sales surge, COVID vax sales sink, 'junk' patentsMay 3Bruce GilBy Bruce Gilmore_vert
The Wall Street JournalNovo Nordisk Stock Falls After Pricing Pressure Mounts for WegovyMay 2Peter LoftusBy Peter Loftusmore_vert
Simply Wall StResults: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New ForecastsMay 4more_vert
Proactive Investors UKNovo Nordisk continues to impress, says buyer CitiMay 3Philip Whiterow & William FarringtonBy Philip Whiterow & William Farringtonmore_vert
Fox Business25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker saysMay 3Daniella Alessandra GenoveseBy Daniella Alessandra Genovesemore_vert
Detroit NewsNovo boosts Wegovy shipments as Lilly rivalry pressures pricesMay 2Naomi KresgeBy Naomi Kresgemore_vert
AOLNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on WegovyMay 2Anjalee KhemlaniBy Anjalee Khemlanimore_vert
FuturismNovo Nordisk To Slash Prices On Buzzy Drugs Ozempic and WegovyMay 3Noor Al-SibaiBy Noor Al-Sibaimore_vert
FiercePharmaFacing pricing pressure from Lilly's Zepbound, Novo Nordisk scales Wegovy supplyMay 2Zoey BeckerBy Zoey Beckermore_vert
AxiosOzempic, Wegovy shortages weigh on Novo Nordisk outlookMay 2Nathan BomeyBy Nathan Bomeymore_vert
ReutersNovo Nordisk trims price for blockbuster obesity drug as competition heats upMay 2Maggie Fick & Stine Buch JacobsenBy Maggie Fick & Stine Buch Jacobsenmore_vert
FortuneNovo Nordisk expects 27% sales surge this year but faces price pressure amid Eli Lilly competitionMay 2Naomi KresgeBy Naomi Kresgemore_vert
Fast CompanyNovo Nordisk stock price sinks today despite Wegovy sales boomMay 2Ellie StevensBy Ellie Stevensmore_vert
Financial TimesNovo Nordisk cuts price of weight loss drug Wegovy as competition heats upMay 2more_vert
InvestopediaNovo Nordisk's Earnings Beat Estimates on Surging Demand for Its Weight-Loss DrugsMay 2Aaron McDadeBy Aaron McDademore_vert
MorningstarNovo Nordisk Earnings Beat Estimates on Weight Loss SalesMay 3Johanna EnglundhBy Johanna Englundhmore_vert
Investor's Business DailyNovo Nordisk Dips As Wegovy Sales Double, But Miss ForecastsMay 2Allison GatlinBy Allison Gatlinmore_vert
WXOW.comAt least 25000 people in the US are starting weight-loss drug Wegovy each week, drugmaker saysMay 2Meg TirrellBy Meg Tirrellmore_vert
Business InsiderNovo Nordisk plans to cut US price for blockbuster obesity drug WegovyMay 2Shubhangi GoelBy Shubhangi Goelmore_vert
Proactive Investors USANovo Nordisk ups guidance buts cuts Wegovy priceMay 2Oliver Haill & Philip WhiterowBy Oliver Haill & Philip Whiterowmore_vert
Barron'sNovo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.May 2Josh Nathan-kazis & Callum KeownBy Josh Nathan-kazis & Callum Keownmore_vert
The Wall Street JournalWegovy Sales More Than Double as Demand SoarsMay 2Dominic ChoppingBy Dominic Choppingmore_vert
BloombergNovo Trades at Hefty Discount to Lilly Even After 350% RallyMay 2Kit Rees & Thyagaraju AdinarayanBy Kit Rees & Thyagaraju Adinarayanmore_vert
The GuardianDanish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bnMay 2Julia KolleweBy Julia Kollewemore_vert
CNBCWegovy maker Novo Nordisk extends losses following first-quarter resultsMay 3Jenni ReidBy Jenni Reidmore_vert
Sky NewsNovo Nordisk's results are stunning - and it could be on the brink of something even more excitingMay 2Ian KingBy Ian Kingmore_vert
Yahoo News AustraliaWeight loss drug wins 25,000 new US users a weekMay 20Natalie ShermanBy Natalie Shermanmore_vert
Yahoo Canada FinanceNovo Nordisk To Slash Prices On Buzzy Drugs Ozempic and WegovyMay 3Noor Al-SibaiBy Noor Al-Sibaimore_vert